Core Viewpoint - Kolun Pharmaceutical has announced that five of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] Group 1: Financial Impact - The total sales revenue of the aforementioned drugs for the year 2024 is approximately 51.69 million yuan [1] - For the first half of 2025, the combined sales revenue is expected to be around 309.75 million yuan [1] - These sales figures represent approximately 0.24% and 3.41% of the company's revenue for the respective periods [1]